Ikemoto H
Jpn J Antibiot. 1984 Jan;37(1):111-21.
Micronomicin sulfate (MCR) by intravenous drip infusion for internal field infections was studied in 30 cooperative research institutions and the following results were obtained. Clinical efficacy of MCR on respiratory tract infections was 79.4% for pneumonia, 51.5% for chronic bronchitis and 81.0% for respiratory tract infections associated with bronchiectasis, respectively, with a total effectiveness rate of 70.9%. MCR was effective on urinary tract infections with a rate of 85% and on septicemia with a rate of 80%. There were no cases of clinical symptoms seemed to be adverse reactions. Abnormal laboratory test values were noted in 13 out of 167 cases (7.8%), but all of them were transient without severe reactions observed. It is fully expected that MCR intravenous drip infusion for internal field infection is clinically effective.
30家合作研究机构对硫酸小诺米星（MCR）静脉滴注治疗深部感染进行了研究，得出以下结果。MCR对呼吸道感染的临床疗效分别为：肺炎79.4%，慢性支气管炎51.5%，支气管扩张合并呼吸道感染81.0%，总有效率为70.9%。MCR对尿路感染的有效率为85%，对败血症的有效率为80%。未出现似乎为不良反应的临床症状病例。167例中有13例（7.8%）实验室检查值异常，但均为一过性，未观察到严重反应。完全可以预期，MCR静脉滴注治疗深部感染在临床上是有效的。
